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Although evidence has suggested that the serine/threonine protein phosphatase 2A 
(PP2A) might be a tumor suppressor protein, it has been difficult to pin down its role in 
tumor suppression because it acts in a wide variety of signaling pathways. Recent find-
ings, including work in this issue by Junttila et al. (2007), provide convincing evidence that 
suppression of PP2A activity cooperates with other oncogenic changes to cause transfor-
mation of multiple cell types.The unrestricted growth of transformed cells is caused 
by the cumulative dysregulation of multiple cellular path-
ways involved in normal growth control. Although a large 
number of distinct genetic changes occur in individual 
cancers, accumulating evidence suggests that a limited 
number of alterations comprise a core set of changes 
required for transformation. In human cells, this set of 
changes includes the expression of telomerase, the acti-
vation of Ras, and the inactivation of the tumor suppres-
sor proteins RB and p53 (Hanahan and Weinberg, 2000; 
Hahn and Weinberg 2002). Although these changes are 
sufficient to immortalize human cells, they do not induce 
a fully transformed phenotype (as defined by anchorage-
independent growth and formation of tumors in immune-
deficient mice). Recent evidence indicates that suppres-
sion of protein phosphatase 2A (PP2A) activity is an 
additional alteration needed to push these immortalized 
cells over the precipice that leads to complete transfor-
mation (Junttila et al., 2007; Sablina et al., 2007).
PP2A is a ubiquitously expressed protein serine/thre-
onine phosphatase that accounts for a large fraction of 
phosphatase activity in eukaryotic cells. PP2A is not a 
single entity but rather a large collection of oligomeric 
enzymes that contain a common catalytic subunit. The 
most common forms of PP2A contain an active core 
dimer composed of the catalytic subunit and a scaffold 
protein termed the A subunit. The scaffold subunit medi-
ates interaction of the core dimer with a wide variety of 
regulatory subunits (B subunits) that dictate the func-
tions of individual forms. Multiple families, isoforms, and 
splice variants of the regulatory subunits allows genera-
tion of over 60 different heterotrimeric PP2A holoen-
zymes (Janssens and Goris, 2001). The regulatory sub-
units typically enhance the formation of stable complexes 
between PP2A and its substrates. PP2A has the remark-
able ability to interact with structurally distinct regula-
tory subunits and to form complexes with many different 
substrates due to the inherent flexibility of the scaffold 
subunit, which is composed of 15 tandem HEAT repeats. The recent solution of the three-dimensional structure of 
a PP2A holoenzyme has shown that the scaffold subunit 
undergoes dramatic structural rearrangements follow-
ing interaction with the catalytic and regulatory subunits 
(Xing et al., 2006; Xu et al., 2006; Cho and Xu, 2007). 
Thus, in addition to diversity generated by the regulatory 
subunits, flexibility within the PP2A structure provides 
additional adaptability in substrate recognition. These 
properties help to account for the large and growing list 
of phosphoproteins and signaling pathways known to be 
affected by PP2A.
However, the ubiquitous action of PP2A in many cel-
lular processes has been an impediment to defining its 
role in tumor suppression. Manipulation of the shared 
catalytic or scaffold subunits (for instance with inhibi-
tors) affects the phosphorylation of hundreds, or even 
thousands, of proteins. An additional complication is 
that PP2A is essential for viability—complete inhibition 
of PP2A or loss of the catalytic or scaffold subunits by 
gene deletion or RNA interference causes cell death. 
The tumor suppressive function of PP2A has been hiding 
behind this morass of signaling pathways and the lethal 
effects of its inhibition. Fortunately, recent advances 
have begun to tease apart the functions of PP2A in cel-
lular transformation and other processes.
The first hint of PP2A’s tumor suppressing activity 
came from studies in which okadaic acid, a selective 
but not specific inhibitor of PP2A, was shown to potently 
promote tumors in a mouse model of carcinogenesis. 
The second clue came with the discovery that PP2A 
was the target of the small tumor antigen (small-t) of 
two transforming DNA viruses, SV40 and polyoma virus 
(reviewed in Arroyo and Hahn, 2005). Small-t disrupts 
PP2A by binding to the A subunit and displacing the reg-
ulatory subunits but not the catalytic subunit. The result-
ing loss in targeting inhibits PP2A activity and enhances 
phosphorylation of proteins involved in controlling cell 
growth. However, the role of the interaction between 
small-t and PP2A in transformation remained uncertain Cell 130, July 13, 2007 ©2007 Elsevier Inc. 21
Figure 1. Suppression of PP2A Activity 
Cooperates in Transformation
A core set of changes including inactivation of 
p53 and RB by SV40 large T antigen (LT), ex-
pression of active telomerase (hTERT), and ex-
pression of an active Ras (H-RAS) can immor-
talize human cells. In this setting, expression 
of the fully transformed phenotype requires 
suppression of PP2A activity. Multiple mecha-
nisms for inhibiting PP2A exist in transformed 
cells (boxes), including expression of SV40 
small tumor antigen (SV40 small-t), upregula-
tion of CIP2A (cancerous inhibitor of PP2A), 
or inactivation of the Aβ scaffold subunit by 
mutations. These inhibitory mechanisms lead 
to enhanced phosphorylation and activity of 
tumorigenic proteins, including the c-Myc 
transcription factor, the Akt protein kinase, 
and RalA GTPase. Suppression of phospha-
tase activity toward any one of these proteins 
is sufficient to induce full transformation. The 
fact that all of these tumorigenic proteins are 
downstream targets of activated Ras (indicat-
ed by dashed lines) argues that a major tumor 
suppressing activity of PP2A is to antagonize 
Ras signaling.due to the use of rodent cultured cell lines, which do 
not require small-t for transformation when SV40 large T 
antigen is present. An important function for this interac-
tion has been established in human cells in which small-t 
is required for transformation (Yu et al., 2001; Hahn et 
al., 2002). These cells cannot be transformed by mutant 
forms of small-t that are unable to interact with, and 
thereby inhibit, PP2A.
Establishment of a transformation model dependent 
on small-t has allowed several groups to identify path-
ways and proteins that are involved in the tumor sup-
pressive activity of PP2A. William Hahn and colleagues 
have explored the role of PP2A using immortalized but 
nontumorigenic cells, termed HEK TER cells. HEK TER 
cells are human embryonic kidney cells expressing a 
combination of SV40 large T antigen, which inactivates 
RB and p53, the catalytic subunit of human telomerase, 
and an oncogenic GTPase-deficient version of H-Ras 
(Chen et al., 2004). Expression of small-t in these cells 
results in anchorage-independent cell growth and tumor 
formation in mice. Identification of factors that can sub-
stitute for small-t in transformation of these cells has 
led to the identification of important components and 
targets of PP2A (Figure 1). For example, the transform-
ing activity of small-t is largely dependent on displace-
ment of a single type of PP2A regulatory subunit (B56γ) 
from PP2A complexes (Chen et al., 2004). In addition, 
partial knockdown of the Aα subunit results in selective 
loss of PP2A heterotrimers containing the B56γ subunit, 
and loss of B56γ from PP2A complexes substitutes for 
small-t during transformation. The partial suppression of 
endogenous Aα leads to activation of Akt kinase, sug-
gesting that activation of the PI-3 kinase/Akt pathway 
contributes to the transformation caused by the sup-22 Cell 130, July 13, 2007 ©2007 Elsevier Inc.pression of PP2A activity (Chen et al., 2005). c-Myc is 
also a target of PP2A regulation. PP2A holoenzymes 
containing the B56α regulatory subunit dephosphory-
late c-Myc at Ser62 in the transactivation domain, result-
ing in its ubiquitination and degradation. A c-Myc mutant 
that cannot be dephosphorylated by PP2A can replace 
small-t in the transformation of HEK TER cells (Arnold 
and Sears, 2006).
New Mechanisms for Suppressing PP2A in 
Transformed Cells
Most cellular PP2A holoenzymes contain the Aα isoform 
of the scaffold subunit, but a small fraction (10%) contain 
a second isoform termed Aβ. Although they are 86% iden-
tical, Aβ has distinct biochemical properties and cannot 
substitute for the loss of Aα in transgenic mice. Although 
mutations that disrupt the ability of Aβ to form holoen-
zymes in vitro were identified in several types of cancer 
(Ruediger et al., 2001; Xu et al., 2006; Cho and Xu, 2007), 
the recent report by Sablina et al. (2007) provides the first 
hard evidence that loss of functional Aβ due to these can-
cer-associated mutations contributes to transformation. 
Knockdown of Aβ in HEK TER cells with a short hairpin 
RNA (shRNA) increased the rate of proliferation, conferred 
anchorage-independent growth, and imbued the cells 
with the ability to form tumors in immunodeficient mice. 
In contrast, knockdown of the Aα isoform of the scaffold 
subunit inhibited proliferation. The ability of Aβ shRNA to 
induce tumorigenicity was blocked by expression of an 
RNAi-resistant form of wild-type Aβ but not by Aβ proteins 
containing the cancer-associated mutations.
Sablina et al. (2007) also showed that wild-type Aβ 
can reverse the tumorigenic phenotype of patient-
derived lung carcinoma cell lines harboring mutations in 
Aβ. They found that exogenous expression of wild-type 
Aβ inhibited cell growth, anchorage-independent colony 
formation, and tumor growth of cancer lines in which 
both alleles of the Aβ gene were defective. Cells lines 
containing at least one wild-type allele were not affected, 
indicating that loss-of-function of both Aβ alleles is nec-
essary for transformation. The decrease in prolifera-
tion of lung carcinoma cells expressing Aβ was due to 
lengthening of the cell cycle and not to apoptosis.
The report by Junttila et al. in this issue identifies a 
unique mechanism for suppression of PP2A activity in 
transformed cells. This group identified proteins that 
interact with the Aα subunit in human HT-1080 fibrosar-
coma cells using a proteomic approach. Their screen 
identified a 90 kDa protein of unknown function that is 
overexpressed in hepatocellular carcinoma and gastric 
cancers (Soo et al., 2002). Based on subsequent analy-
sis it was termed CIP2A (cancerous inhibitor of PP2A).
Knockdown of CIP2A in HeLa cells, which express high 
levels of CIP2A, resulted in decreased cell proliferation 
and blocked their ability to form colonies in soft agar and 
to form tumors in athymic mice. Ectopic expression of 
CIP2A and activated Ras in spontaneously immortalized, 
but nonmalignant, mouse embryo fibroblasts caused an 
increase in focus formation relative to expression of Ras 
alone. Expression of CIP2A in HEK TER cells also resulted 
in an increase in anchorage-independent growth. CIP2A 
expression is shown to be upregulated in transformed cell 
lines and cancer tissue samples. Consistent with a role of 
CIP2A in transformation, knockdown of CIP2A in squa-
mous cell carcinoma cell lines expressing high levels of 
CIP2A markedly decreases cell growth, anchorage-inde-
pendent colony formation, and tumor growth.
RalA and c-Myc Are Tumorigenic Substrates  
of PP2A
In addition to helping to establish PP2A as a bona fide 
tumor suppressor, the papers by Sablina et al. (2007) and 
Junttila et al. (2007) identified PP2A substrates involved 
in the suppression of tumorigenicity. Sablina et al. also 
used a proteomic approach to identify proteins that 
coimmunoprecipitated with the Aα or Aβ scaffold sub-
units. The GTPase RalA specifically forms complexes 
with the Aβ subunit. Aβ proteins harboring the cancer-
associated mutations could not interact with RalA, sug-
gesting that the interaction with RalA is dependent on 
the incorporation of Aβ into PP2A holoenzymes. These 
data demonstrate that PP2A holoenzymes containing 
the Aβ scaffold subunit, but not those containing the Aα 
scaffold subunit, form complexes with RalA. This is an 
important observation, as a previous study showed that 
a constitutively active form of RalA could substitute for 
activated Ras in transformation of HEK TER cells that 
also express small-t antigen (Lim et al., 2005).
Knockdown of RalA inhibited the ability of HEK TER 
cells expressing Aβ shRNA to form colonies in soft agar. 
The link between Aβ and RalA was further strength-
ened by data showing that knockdown of Aβ resulted in increased RalA activity, whereas overexpression of wild-
type Aβ decreased RalA activity. A lung carcinoma cell 
line expressing mutant Aβ had 4-fold higher RalA activity 
than cell lines carrying wild-type Aβ. These results indi-
cate that activation of RalA is necessary for the transfor-
mation of HEK TER cells caused by loss of functional Aβ.
The link between RalA and tumor suppression by 
Aβ implies that PP2A regulates RalA activity through 
dephosphorylation. Although a major mode of RalA 
regulation is through Ras-dependent activation of Ral 
guanine nucleotide exchange factors (RalGEFs), a previ-
ous study showed that RalA can be phosphorylated on 
Ser194 by Aurora A kinase and that overexpression of 
Aurora A increases RalA activity and anchorage-inde-
pendent growth of MDCK cells (Wu et al., 2005). Sablina 
et al. used phosphorylation site mutants to show that 
phosphorylation of Ser183 and Ser194 increases RalA 
activity in HEK TER cells. RalA phosphorylation on these 
residues was increased in cells depleted of Aβ by shRNA. 
Moreover, phosphorylation of these sites in cancer cell 
lines harboring mutant forms of Aβ was greater than in 
lines containing wild-type Aβ. In addition, the Ser183 and 
Ser194 phosphorylation site mutants of RalA could not 
complement the loss of RalA activity in cells depleted of 
RalA. The results establish that constitutive phosphory-
lation of RalA in HEK TER cells lacking functional Aβ is a 
major mechanism contributing to transformation.
Junttila et al. (2007) took a different approach to 
identify PP2A substrates important in the transforming 
activity of CIP2A. As previous data indicated that PP2A 
regulates the transcriptional activity of p53 and c-Myc, 
they reasoned that CIP2A might affect genome-wide 
transcriptional profiles by suppressing PP2A activity. 
Transcriptional profiles from HeLa cells transfected with 
CIP2A siRNA were compared to those from cells trans-
fected with a scrambled version of the siRNA. The tran-
scriptional changes induced by the CIP2A knockdown 
were then compared to databases of genes regulated by 
p53 or c-Myc. A significant number (16%) of the genes 
affected by CIP2A knockdown were known targets of c-
Myc, whereas very few were targets of p53. Together 
with data showing that PP2A regulates the stability of 
c-Myc, Junttila et al. (2007) provide strong evidence that 
CIP2A regulates c-Myc function.
Subsequent experiments verified that CIP2A inhib-
its dephosphorylation of c-Myc at Ser62 and increases 
the level of c-Myc protein by inhibiting its degradation. 
Knockdown of CIP2A in HeLa cells decreased phosphor-
ylation of c-Myc on Ser62, showing that CIP2A inhibits 
dephosphorylation of this site. The inhibition was spe-
cific for c-Myc dephosphorylation, as other substrates of 
PP2A were not affected. The enhanced dephosphoryla-
tion of Ser62 correlated with an increase in PP2A activity 
associated with c-Myc. This increase in activity was due 
to an increase in PP2A catalytic activity and not to the 
amount of PP2A bound to c-Myc. Thus, CIP2A selectively 
targets PP2A associated with c-Myc to inhibit its phos-
phatase activity and protect Ser62 from dephosphory-Cell 130, July 13, 2007 ©2007 Elsevier Inc. 23
lation. Knockdown of CIP2A in squamous cell carcino-
mas expressing high levels of CIP2A led to a decrease 
in c-Myc protein and to an increase in c-Myc-associated 
PP2A phosphatase activity. In addition, the increased 
transformation of HEK TER cells caused by exogenous 
expression of CIP2A coincided with an increase in the 
levels of c-Myc.
Multiple Mechanisms, But a Common Pathway?
There is now convincing evidence that PP2A is a bona fide 
tumor suppressor protein. A variety of mechanisms for 
inhibiting PP2A are present in transformed cells. PP2A is 
inhibited by the small tumor antigen of DNA tumor viruses, 
by upregulation of the c-Myc-specific inhibitor CIP2A, 
through biallelic mutational inactivation of the Aβ subunit, 
or by decreased expression of the Aα subunit (Figure 1). 
In addition, upregulation of another inhibitor, SET, by the 
BCR/ABL oncogene and subsequent suppression of 
PP2A contributes to leukemogenesis (Neviani et al., 2005). 
Although PP2A has many substrates, new data, including 
those published in Cell, indicate that its actions in a few key 
pathways may play dominant roles in its ability to suppress 
tumor growth. It seems an unlikely coincidence that each 
of the PP2A substrates shown to be important in tumor 
suppression are downstream components of Ras signal-
ing. Activated Ras stimulates phosphorylation and activa-
tion of Akt kinase through the PI-3 kinase pathway as well 
as phosphorylation and stabilization of c-Myc through the 
ERK group of MAP kinases. Active Ras stimulates RalA by 
activating RalGEFs. Although the details of RalA regulation 
remain to be determined, phosphorylation stimulates GTP 
loading onto RalA and may enhance activation caused by 
increases in RalGEF activity. PP2A has now been shown to 
antagonize these actions of Ras by directly dephosphor-
ylating c-Myc and RalA and by negatively regulating the 
PI-3 kinase/Akt pathway. Suppression of PP2A therefore 
cooperates with Ras to enhance the activity of these onco-
genic proteins. It appears that suppression of PP2A activ-
ity toward any one of these targets is sufficient to induce 
the fully transformed phenotype. Although altered regula-
tion of the cell cycle and apoptosis (two established roles 
for PP2A) may also be involved, these recent results argue 
that an important action of PP2A in tumor suppression is to 24 Cell 130, July 13, 2007 ©2007 Elsevier Inc.antagonize signaling downstream of activated Ras.
ReFeRenCeS
Arnold, H.K., and Sears, R.C. (2006). Mol. Cell. Biol. 26, 2832–
2844.
Arroyo, J.D., and Hahn, W.C. (2005). Oncogene 24, 7746–7755.
Chen, W., Arroyo, J.D., Timmons, J.C., Possemato, R., and Hahn, 
W.C. (2005). Cancer Res. 65, 8183–8192.
Chen, W., Possemato, R., Campbell, K.T., Plattner, C.A., Pallas, 
D.C., and Hahn, W.C. (2004). Cancer Cell 5, 127–136.
Cho, U.S., and Xu, W. (2007). Nature 445, 53–57.
Hahn, W.C., Dessain, S.K., Brooks, M.W., King, J.E., Elenbaas, B., 
Sabatini, D.M., DeCaprio, J.A., and Weinberg, R.A. (2002). Mol. 
Cell. Biol. 22, 2111–2123.
Hahn, W.C., and Weinberg, R.A. (2002). Nat. Rev. Cancer 2, 331–341.
Hanahan, D., and Weinberg, R.A. (2000). Cell 100, 57–70.
Janssens, V., and Goris, J. (2001). Biochem. J. 353, 417–439.
Junttila, M.R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., 
Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. 
(2007). Cell, this issue.
Lim, K.H., Baines, A.T., Fiordalisi, J.J., Shipitsin, M., Feig, L.A., Cox, 
A.D., Der, C.J., and Counter, C.M. (2005). Cancer Cell 7, 533–545.
Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B.W., Liu, 
S., Mao, H., Chang, J.S., Galietta, A., Uttam, A., et al. (2005). Can-
cer Cell 8, 355–368.
Ruediger, R., Pham, H.T., and Walter, G. (2001). Oncogene 20, 
1892–1899.
Sablina, A.A., Chen, W., Arroyo, J.D., Corral, L., Hector, M., Bulmer, 
S.E., DeCaprio, J.A., and Hahn, W.C. (2007). Cell 129, 969–982.
Soo, H.L., Zhang, J.Y., and Chan, E.K. (2002). Oncogene 21, 5006–
5015.
Wu, J.C., Chen, T.Y., Yu, C.T., Tsai, S.J., Hsu, J.M., Tang, M.J., 
Chou, C.K., Lin, W.J., Yuan, C.J., and Huang, C.Y. (2005). J. Biol. 
Chem. 280, 9013–9022.
Xing, Y., Xu, Y., Chen, Y., Jeffrey, P.D., Chao, Y., Lin, Z., Li, Z., 
Strack, S., Stock, J.B., and Shi, Y. (2006). Cell 127, 341–353.
Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J.W., Strack, 
S., Jeffrey, P.D., and Shi, Y. (2006). Cell 127, 1239–1251.
Yu, J., Boyapati, A., and Rundell, K. (2001). Virology 290, 192–
198.
